Microfluidic preparation of monodisperse polymeric microspheres coated with silica nanoparticles

Abstract

The synthesis of organic-inorganic hybrid particles with highly controlled particle sizes in the micrometer range is a major challenge in many areas of research. Conventional methods are limited for nanometer-scale fabrication because of the difficulty in controlling the size. In this study, we present a microfluidic method for the preparation of organic-inorganic hybrid microparticles with poly (1,10-decanediol dimethacrylate-co-trimethoxysillyl propyl methacrylate) (P (DDMA-co-TPM)) as the core and silica nanoparticles as the shell. In this approach, the droplet-based microfluidic method combined with in situ photopolymerization produces highly monodisperse organic microparticles of P (DDMA-co-TPM) in a simple manner, and the silica nanoparticles gradually grow on the surface of the microparticles prepared via hydrolysis and condensation of tetraethoxysilane (TEOS) in a basic ammonium hydroxide medium without additional surface treatment. This approach leads to a reduction in the number of processes and allows drastically improved size uniformity compared to conventional methods. The morphology, composition, and structure of the hybrid microparticles are analyzed by SEM, TEM, FT-IR, EDS, and XPS, respectively. The results indicate the inorganic shell of the hybrid particles consists of SiO2 nanoparticles of approximately 60 nm. Finally, we experimentally describe the formation mechanism of a silica-coating layer on the organic surface of polymeric core particles.

A Microfluidic Platform to design Multimodal PEG - crosslinked Hyaluronic Acid Nanoparticles (PEG-cHANPs) for diagnostic applications

“…In addition, when microfluidic platforms are used as microreactors, they provide improved space-time yields (product formed per reactor volume and time), producing faster reactions than bulk counterparts. Moreover, the degree of control over local environmental conditions is such to guarantee homogeneous products [33][34][35][36] .…”

An ultraviolet‐curable, core–shell vaccine formed via phase separation

“…While microfluidics approaches have been used for successfully fabrication of two‐phase systems (Choi et al, ; Ma et al, ), we opted to not use a microfluidic approach initially for the proof‐of‐concept because: (a) generally the size of phase‐separated particles used within such systems range from 0.01–200 μm (Ekanem, Nabavi, Vladisavljevic, & Gu, ; Karnik et al, ; Kim et al, ; Seo et al, ), which would likely require many dozens of the same particles to be delivered, potentially leading to self‐aggregation and undesirable and unpredictable kinetics; (b) the amount of drug in contact with an organic solvent is far higher (Figure S1), which would increase the cost of the system due to cargo denaturation issues; and (c) the diameter of microfluidic‐formed approaches generally result in more of a continuous release fashion, which may result in T cell anergy. In the future, we plan to investigate macrofluidic approaches, as opposed to microfluidics.…”

Cell‐free protein synthesis: The transition from batch reactions to minimal cells and microfluidic devices

“…Developing novel platforms for biomedical, diagnostic, biosensing, and monitoring purposes is an unprecedented opportunity microfluidic‐based devices have offered. Precise control over the geometries of the chips and flow rates of fluids of different phases, presented by microfluidic devices, enables the generation of uniform, highly stable, mono‐dispersed particles with improved encapsulation turnover (Kim et al, 2018; Xu et al, 2005). On that account, unique advantages in developing prompt drug screening techniques with optimized CFPS, and efficacious drug carriers are offered by microfluidic devices (Damiati, Kompella, Damiati, & Kodzius, 2018).…”